Regulations.gov document
Lonza Inc. A Pivotal Maximal Use Study to Measure the Systemic Absorption of Benzalkonium…
Supporting & Related Material · FDA-2016-N-0124 · posted Jun 29, 2020
Key facts
| Document ID | FDA-2016-N-0124-0384 |
|---|---|
| Title | Lonza Inc. A Pivotal Maximal Use Study to Measure the Systemic Absorption of Benzalkonium Chloride (BAC) after Exaggerated Use of the Antimicrobial Soap on Intact Skin in Healthy Volunteers re Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2016-N-0124 |
| Posted | Jun 29, 2020 |
At a glance
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: